Meta-analysis of the expression of BRCA1 in gastric cancer tissues and the prognosis of platinum drugs

ZHANG Mao, LIU Pengcheng, ZHAO Tianyong, TANG Qi, MENG Xiangyu

Journal of Baotou Medical College ›› 2024, Vol. 40 ›› Issue (11) : 41-45.

PDF(1483 KB)
PDF(1483 KB)
Journal of Baotou Medical College ›› 2024, Vol. 40 ›› Issue (11) : 41-45. DOI: 10.16833/j.cnki.jbmc.2024.11.009

Meta-analysis of the expression of BRCA1 in gastric cancer tissues and the prognosis of platinum drugs

  • ZHANG Mao1, LIU Pengcheng2, ZHAO Tianyong2, TANG Qi3, MENG Xiangyu3
Author information +
History +

Abstract

Objective: To explore the expression of breast cancer susceptibility gene 1 (BRCA1) in gastric malignant tumor tissues and the prognosis after platinum-based chemotherapy by meta-analysis. Methods: Key words such as "breast cancer susceptibility gene 1 (BRCA1)" "gastric malignant tumor" "expression" "platinum chemotherapeutic drugs" "prognosis" were searched in CNKI, PubMed, Embase, Wanfang, VIP and other databases. After screening the literature, the general situation and data of the included literature were recorded. Meta-analysis was performed using RevMan.5.4 software. Results: Finally, 12 articles were included, with 2 826 patients. The odds ratio(OR)and 95% confidence interval(95%CI)were regarded as effect indicators, and according to the analysis and statistics, the results showed that the expression of BRCA1 in gastric cancer tissues with different depth of invasion, lymph node metastasis, different degree of differentiation and clinical TNM stage was statistically significant(P<0.05), and it was correlated with tumor diameter (P<0.05). The 3-year disease free survival (DFS) and overall surviva(OS)of BRCA1-negative patients after platinum-based chemotherapy were higher than those of BRCA1-positive patients. Conclusion: BRCA1 is associated with the clinicopathological features of gastric cancer, and this gene affects the efficacy and prognosis of platinum-based chemotherapy for gastric cancer.

Key words

Breast cancer susceptibility gene 1(BRCA1) / Gastric cancer / Platinum based chemotherapy drugs / Meta-analysis

Cite this article

Download Citations
ZHANG Mao, LIU Pengcheng, ZHAO Tianyong, TANG Qi, MENG Xiangyu. Meta-analysis of the expression of BRCA1 in gastric cancer tissues and the prognosis of platinum drugs[J]. Journal of Baotou Medical College, 2024, 40(11): 41-45 https://doi.org/10.16833/j.cnki.jbmc.2024.11.009

References

[1] 常敏, 张久聪, 周琴, 等. 胃癌流行病学研究进展[J]. 胃肠病学和肝病学杂志, 2017, 26(9): 966-969.
[2] 宋杰, 陈凤格, 赵伟, 等. 胃癌的发病率现状与治疗研究进展[J]. 中国慢性病预防与控制, 2016, 24(9): 704-707.
[3] 薛伟男. 乳腺癌BRCA1基因研究进展[J]. 实用肿瘤学杂志, 2010, 24(3): 290-292,300.
[4] Wang GH, Zhao CM, Huang Y, et al. BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers[J]. Hum Pathol, 2018, 71: 135-144.
[5] Kim JW, Cho HJ, Kim M,et al. Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer[J]. Cancer Chemother Pharmacol, 2013, 71(6): 1435-1443.
[6] Chen W, Wang J, Li X, et al. Prognostic significance of BRCA1 expression in gastric cancer[J]. Med Oncol, 2013, 30(1): 423.
[7] 姬玉, 王建, 吴昊, 等. BRCA1表达与Ⅲ期胃腺癌患者术后特异性生存的关系[J]. 肿瘤预防与治疗, 2021, 34(4): 286-294.
[8] 林莉, 常建宁, 王建, 等. 进展期胃癌患者乳腺癌易感基因1的表达及意义[J]. 江苏医药, 2015(14): 1666-1668.
[9] 林雅萍, 李厚强, 苏慧君, 等. TS和BRCA1在胃癌组织中的表达及其临床意义[J]. 世界华人消化杂志, 2013, 21(15): 1421-1427.
[10] 梁发. ERCC1与BRCA1在胃癌组织中的表达及临床意义[D]. 湛江: 广东医学院, 2011.
[11] 顾术东, 茅国新. 胃癌BRCA1的表达与奥沙利铂方案辅助化疗疗效及预后的关系[J]. 广东医学, 2013, 34(22): 3407-3410.
[12] 高福平. Her-2、p63、BRCA1在胃癌中的表达及意义[D]. 苏州: 苏州大学, 2012.
[13] 张伟, 尹晓东. LncRNA HOTAIR与BRCA-1在胃癌组织中的表达水平与顺铂化疗抵抗的影响[J]. 临床与病理杂志, 2020, 40(2): 290-295.
[14] 林武华. 胃癌组织中乳腺癌易感基因1表达状况与奥沙利铂方案辅助化疗疗效、预后的相关性[J]. 世界华人消化杂志, 2015, 23(15): 2440-2444.
[15] 陈艳, 严必中, 陈平, 等. 胃癌患者乳腺癌易感基因1与X射线修复交叉互补基因1的表达及其奥沙利铂辅助化疗效果分析[J]. 实用医院临床杂志, 2016, 13(1): 38-40.
[16] 崔方博, 高尔云, 胡楠. 乳腺癌易感基因1和微管蛋白β3在胃癌中的表达及其临床意义[J]. 肿瘤研究与临床, 2021, 33(8): 601-605.
[17] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[18] Qiu MZ, Wang ZX, Zhou YX, et al. Proposal for a new TNM stage based on the 7th and 8th American Joint Committee on Cancer pTNM staging classification for gastric cancer[J]. J Cancer, 2018, 9(19): 3570-3576.
[19] Sahasrabudhe R, Lott P, Bohorquez M, et al. Germline mutations in PALB2, BRCA1, and RAD51C, which regulate DNA recombination repair, in patients with gastric cancer[J]. Gastroenterology, 2017, 152(5): 983-986, e6.
[20] 余玲玲, 奉林, 张允, 等. BRCA1多态性与晚期胃癌铂类化疗敏感性及预后关系[J]. 肿瘤预防与治疗, 2021, 34(4): 306-312.
[21] Werner H. BRCA1: An endocrine and metabolic regulator[J]. Front Endocrinol (Lausanne), 2022, 13: 844575.
[22] Takaoka M, Miki Y. BRCA1 gene: function and deficiency[J]. Int J Clin Oncol, 2018, 23(1): 36-44.
[23] Sun H, Zeng J, Miao Z, et al. Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing[J]. Theranostics, 2021, 11(20): 9967-9987.
[24] Yoshino Y, Fang Z, Qi H, et al. Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis[J]. Cancer Sci, 2021, 112(5): 1679-1687.
[25] Minucci A, Mazzuccato G, Marchetti C, et al. Detecting large germline rearrangements of BRCA1 by next generation tumor sequencing[J]. Mol Biol (Mosk), 2020, 54(4): 688-698.
PDF(1483 KB)

30

Accesses

0

Citation

Detail

Sections
Recommended

/